Get started
Akebia Therapeutics, Inc.Akebia Therapeutics, Inc.Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

AKBA chart


Full chart

AKBA upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪496.34 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.33 USD
Net income (FY)
‪−69.41 M‬ USD
Revenue (FY)
‪160.18 M‬ USD
Shares float
‪250.51 M‬
Beta (1Y)
1.38

Employees


Employees (FY)
181
Change (1Y)
+14 +8.38%
Revenue / Employee (1Y)
‪884.97 K‬ USD
Net income / Employee (1Y)
‪−383.48 K‬ USD

About Akebia Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
John P. Butler
Website
akebia.com
Headquarters
Cambridge
Founded
2007
FIGI
BBG000R33R00
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

AKBA news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as AKBA.

Frequently Asked Questions


The current price of AKBA is 2.06 USD — it has increased by 8.42% in the past 24 hours. Watch Akebia Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Akebia Therapeutics, Inc. stocks are traded under the ticker AKBA.
AKBA stock has risen by 23.35% compared to the previous week, the month change is a −13.45% fall, over the last year Akebia Therapeutics, Inc. has showed a 47.14% increase.
We've gathered analysts' opinions on Akebia Therapeutics, Inc. future price: according to them, AKBA price has a max estimate of 10.00 USD and a min estimate of 6.00 USD. Watch AKBA chart and read a more detailed Akebia Therapeutics, Inc. stock forecast: see what analysts think of Akebia Therapeutics, Inc. and suggest that you do with its stocks.
AKBA reached its all-time high on Jun 20, 2014 with the price of 31.00 USD, and its all-time low was 0.24 USD and was reached on Oct 24, 2022. View more price dynamics on AKBA chart.
See other stocks reaching their highest and lowest prices.
AKBA stock is 12.11% volatile and has beta coefficient of 1.38. Track Akebia Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Akebia Therapeutics, Inc. there?
Today Akebia Therapeutics, Inc. has the market capitalization of ‪538.14 M‬, it has increased by 11.18% over the last week.
Yes, you can track Akebia Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Akebia Therapeutics, Inc. is going to release the next earnings report on May 12, 2025. Keep track of upcoming events with our Earnings Calendar.
AKBA earnings for the last quarter are −0.10 USD per share, whereas the estimation was −0.081 USD resulting in a −23.87% surprise. The estimated earnings for the next quarter are −0.045 USD per share. See more details about Akebia Therapeutics, Inc. earnings.
Akebia Therapeutics, Inc. revenue for the last quarter amounts to ‪46.50 M‬ USD, despite the estimated figure of ‪37.34 M‬ USD. In the next quarter, revenue is expected to reach ‪44.88 M‬ USD.
AKBA net income for the last quarter is ‪−22.80 M‬ USD, while the quarter before that showed ‪−20.04 M‬ USD of net income which accounts for −13.80% change. Track more Akebia Therapeutics, Inc. financial stats to get the full picture.
No, AKBA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 18, 2025, the company has 181 employees. See our rating of the largest employees — is Akebia Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Akebia Therapeutics, Inc. EBITDA is ‪−8.71 M‬ USD, and current EBITDA margin is −5.44%. See more stats in Akebia Therapeutics, Inc. financial statements.
Like other stocks, AKBA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Akebia Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Akebia Therapeutics, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Akebia Therapeutics, Inc. stock shows the buy signal. See more of Akebia Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.